qualigen therapeutics, inc

A high-level overview of Qualigen Therapeutics, Inc. (QLGN) stock. Qualigen Therapeutics Inc QLGN Financials 2022. Qualigen Therapeutics Inc ( QLGN) is up 65.60% today. Here's the Reason Why Qualigen, Inc. (QLGN) Stock is on a Boom About Qualigen Therapeutics, Inc. Qualigen is a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its . The stock is currently down 56.8% year-to-date, down 58.5% over the past 12 months, and down. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target . The price has been going up and down for . Qualigen Therapeutics Inc. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. Founded in 2008, Qualigen Therapeutics Inc has a 52 week high price of 4.66 and a 52 week low price of 1.12. (RTTNews) - Qualigen Therapeutics, Inc. (QLGN) shares are surging more than 47 percent on Tuesday morning trade, continuing an upsurge since November 18. Premarket Mover: Qualigen Therapeutics Inc (QLGN) Up 0.92%. Press Release reported on 11/18/21 that Small Pharma Strengthens Board Wi Qualigen Therapeutics Inc. (NASDAQ: QLGN) Stock: Up 40.91% Since Low, This Stock Is Just Getting Warmed Up stocksregister 4 days ago. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack ® System, which has been used successfully in diagnostics for 20 years. Qualigen Therapeutics Inc. (NASDAQ:QLGN) shares, rose in value on Thursday, 01/06/22, with the stock price up by 4.81% to the previous day's close as strong demand from buyers drove the stock to $1.09. Press Release reported on 11/18/21 that Small Pharma Strengthens Board Wi News Qualigen Therapeutics Inc.QLGN. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING. Qualigen Therapeutics Inc Shares Close the Day 29.0% Higher - Daily Wrap Nasdaq 25/12/2021 Qualigen Therapeutics Inc. (QLGN): Lucky investors are lined up for success Kruger Kurt H, the Director at Qualigen Therapeutics Inc. (QLGN) has bought 8,000 shares of firm on Aug 19 at a price of $1.23 against the total amount of $9800.0. Qualigen Therapeutics Inc has a marketcap of 34,798,597 and an average trading volume of 161,621. Qualigen Therapeutics Inc. (NASDAQ:QLGN) shares, rose in value on Thursday, 01/06/22, with the stock price up by 4.81% to the previous day's close as strong demand from buyers drove the stock to $1.09. The company's stock price has collected 16.82% of gains in the last five trading sessions. QLGN News: QUALIGEN THERAPEUTICS, INC. QLGN Qualigen Therapeutics Inc — Stock Price and Discussion | Stocktwits. QLGN stock closed at $1.09 and is up $0.01 during pre-market trading. QLGN's short-term technical score of 6 indicates that the stock has traded less bullishly over the last month than 94% of stocks on the market. Qualigen Therapeutics, Inc. (US:QLGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. The company's cancer. QLGN has an Overall Score of 6. QLGN has an Overall Score of 6. Qualigen Therapeutics, Inc is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. Announces Closing of $8.82 Million Registered Direct Offering Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using nanoparticle coating technology. The Schedule 13D indicates that the investor holds (or held) more . ; The report is based on a probability-adjusted DCF . Qualigen Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. Qualigen Therapeutics Inc. (NASDAQ:QLGN) went up by 25.62% from its latest closing price compared to the recent 1-year high of $4.66. Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship FastPack® diagnostic platform, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 5,880,000 shares of the Company's common . The stock current value is $1.25.Recently in News Qualigen Therapeutics, Inc. is a biotechnology company that is focused on developing therapeutics for the treatment of cancer and infectious diseases. Qualigen Therapeutics Inc (QLGN) shares closed today 13.8% lower than it did at the end of yesterday. Premarket Mover: Qualigen Therapeutics Inc (QLGN) Up 0.92%. Qualigen Therapeutics, Inc., formerly Ritter Pharmaceuticals, Inc., is a biotechnology company. Qualigen Therapeutics Inc ( QLGN) is up 0.92% today. About Qualigen Therapeutics, Inc. Qualigen is a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its . No news for in the past two years. The company's stock price has collected -32.35% of loss in the last five trading sessions. Actively observing the price movement in the last trading, the stock closed the session at $1.04 The company's stock price has collected 16.82% of gains in the last five trading sessions. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. At the close of trading, the stock's price was $1.14, to imply a decrease of -3.39% or -$0.04 in intraday trading. Qualigen Therapeutics, Inc. is a biotechnology company that is focused on developing therapeutics for the treatment of cancer and infectious diseases. Qualigen Therapeutics Inc. (NASDAQ:QLGN) went down by -6.33% from its latest closing price compared to the recent 1-year high of $4.66. Qualigen Therapeutics, Inc. Quarterly revenues increased 38% to approximately $1.2 million, compared to approximately $0.8 million in the same quarter of the previous yearYear-to-date revenues increased 30% to $4.2 million, compared to $3.2 million in the same nine-month period of the previous yearCash equivalents of approximately $12.3 million as . carlsbad, calif., nov. 15, 2021 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a biotechnology company focused on developing novel therapeutic products for the treatment of adult. QLGN stock closed at $1.09 and is up $0.01 during pre-market trading. Qualigen Therapeutics Inc ( QLGN) is up 0.92% today. QLGN News: Qualigen Therapeutics EPS beats by $0.11, misses on revenue. Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with certain institutional investors for the purchase and sale of 5,880,000 shares of common stock for $1.50 per share (i.e., for aggregate gross proceeds of $8,820,000).. A.G.P./Alliance Global Partners acted as sole placement agent for the offering. Qualigen Therapeutics Inc QLGN Financials 2022. Qualigen Therapeutics Announces Inclusion in Russell Microcap® Index Globe NewsWire - Tue Jun 8, 2021 . Announces Closing of $8.82 Million Registered Direct Offering GlobeNewswire Inc. - 12/1/2021 3:25:00 PM: QUALIGEN THERAPEUTICS, INC. Qualigen Therapeutics Inc ( QLGN) has fallen Thursday morning, with the stock losing -3.23% in pre-market trading to 1.2. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price . In that particular session, Stock kicked-off at the price of $1.00 while reaching the peak value of $1.40 and lowest value recorded on the day was $0.9432. Qualigen Therapeutics Inc (QLGN) Up 65.60% in Premarket Trading. Qualigen Therapeutics, Inc. (QLGN) Stock on the Rise Following IND Submission for Novel Covid-19 Treatment, QN-165 Qualigen Therapeutics, Inc. (QLGN) stock prices were up 1.6854% as of the market opening on July 14th, 2021, with premarket trading having seen the stock The FastPack ® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002. Qualigen Therapeutics Inc (NASDAQ:QLGN) shares are trading higher after a Zack's Small Cap research note showed a $9 price target on the stock. qualigen therapeutics, inc. (nasdaq: qlgn), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship fastpack® diagnostic platform, announced that it has entered into definitive agreements with institutional investors for the purchase and sale of … The Company's cancer therapeutics pipeline . The Company's cancer therapeutics pipeline includes ALAN . The 1-year high price for the company's stock is recorded $4.4340 on 02/16/21, with the lowest value was $0.9295 for the same time period, recorded on 11/18/21. Qualigen is a biotechnology company committed to developing new therapeutics for adult and pediatric patients with rare cancers, as well as expansion of its flagship FastPack ® diagnostic platform. Find out what this means to you and get the rest of the rankings on QLGN! Qualigen Therapeutics Inc. stock price took a fall of -6.96% on Friday(Updated on Dec 31, 2021) The Qualigen Therapeutics Inc. stock price fell by -6.96% on the last day (Friday, 31st Dec 2021) from $1.15 to $1.07. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack ® System, which has been used successfully in diagnostics for 20 years. Qualigen Therapeutics Inc NASDAQ Updated Dec 23, 2021 12:59 AM. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack ® System, which has been used successfully in diagnostics for 20 years. Qualigen Therapeutics, Inc. is a biotechnology company that is focused on developing therapeutics for the treatment of cancer and infectious diseases. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core . Find out what this means to you and get the rest of the rankings on QLGN! The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARSâ„¢. The Company's cancer therapeutics pipeline includes QN-247, RAS-F and STARS. ©2021 Qualigen Therapeutics, Inc. (NASDAQ: QLGN) Privacy Policy; Terms of Service CARLSBAD, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship FastPack® diagnostic platform, today announced that it has entered into definitive agreements with institutional investors for the purchase and . 11/29/2021 10:50:00 AM. Qualigen Therapeutics Inc. (NASDAQ:QLGN) went up by 25.62% from its latest closing price compared to the recent 1-year high of $4.66. In the Biotechnology industry, which ranks 139 out of 146 industries, the . carlsbad, calif., nov. 29, 2021 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer,. Key Data. Find out what this means to you and get the rest of the rankings on QLGN! The company is focused on the development and commercialization of therapeutic drugs for the treatment of cancer and infectious diseases, as well as the development of its FastPack diagnostic platform. At the end of the latest market close, Qualigen Therapeutics Inc. (QLGN) was valued at $1.00. Qualigen Therapeutics, Inc. is a biotechnology company that is focused on developing therapeutics for the treatment of cancer and infectious diseases. About Qualigen Therapeutics Inc. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. Qualigen Therapeutics, Inc. (US:QLGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Currently, 0.10 percent of Qualigen Therapeutics Inc. shares are owned by insiders, and 8.10 percent are held by financial institutions. Qualigen Therapeutics, Inc., formerly Ritter Pharmaceuticals, Inc., is a biotech company. Press Release reported on 12/14/21 that Qualigen Therapeutics Promotes Founded in 2008, Qualigen Therapeutics Inc has a 52 week high price of 4.66 and a 52 week low price of 1.12. Qualigen, Inc. considers candidates for whom an agency has submitted an unsolicited resume to have been referred by the agency free of any charges or fees. Qualigen Therapeutics Inc ( QLGN) is lower by Monday morning, with the stock falling -4.12% in pre-market trading to 1.63. Qualigen Therapeutics CEO Issues Letter to Stockholders July 13 2020 - 08:00AM PR Newswire (US) Print CARLSBAD, Calif., July 13, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), announced that today Chief Executive Officer Michael Poirier has issued a letter to Qualigen's stockholders. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The company's cancer . In the Biotechnology industry, which ranks 142 out of 146 industries, QLGN ranks . QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. Beware of Job Scams! Qualigen Therapeutics Inc Shares Close the Day 29.0% Higher - Daily Wrap Nasdaq 25/12/2021 Qualigen Therapeutics Inc. (QLGN): Lucky investors are lined up for success CARLSBAD, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral. Qualigen Therapeutics Inc has a marketcap of 34,798,597 and an average trading volume of 161,621. During the day the stock fluctuated 9.52% from a day low at $1.05 to a day high of $1.15. Press Release reported on 12/01/21 that Qualigen Therapeutics, Inc. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. About Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack® System, which has been used successfully in diagnostics for almost 20 years. QLGN 1.00 0.09 (8.26%) Post-Market 0.01 (1.00%) 39,422. Qualigen Therapeutics Inc. insiders own 10.61% of total outstanding shares while institutional holders control 8.67%, with the float percentage being 9.70%. The Company's cancer therapeutics pipeline includes QN-247, RAS-F and STARS. Qualigen Therapeutics, Inc. is a biotechnology company that is focused on developing therapeutics for the treatment of cancer and infectious diseases. Qualigen Therapeutics Inc. (NASDAQ:QLGN)'s traded shares stood at 0.86 million during the last session, with the company's beta value hitting -0.67. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. Qualigen always conducts telephone, in-person, or video conference interviews with job candidates during the recruitment process. Qualigen Therapeutics Pharmaceuticals Driven to Deliver See jobs Follow View all 26 employees About us NASDAQ listed biotechnology company focused on developing treatments for adult and pediatric. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The QLGN share's 52-week hig Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. QLGN's short-term technical score of 24 indicates that the stock has traded less bullishly over the last month than 76% of stocks on the market. 11/15/2021 04:10:59 AM. There were no corporate announcements on . Qualigen Therapeutics, Inc. is a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, as well as maintaining and . Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The company's cancer therapeutics pipeline includes . QLGN stock closed at $1.25 and is up $0.82 during pre-market trading. The QLGN share's 52-week hig carlsbad, calif., sept. 08, 2021 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a biotechnology company focused on developing treatments for adult and pediatric cancers with. QLGN has an Overall Score of 20. Announces Closing of $8.82 Million . Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack ® System, which has been used successfully in diagnostics for 20 years. More About Us Our Therapeutics Pipeline At the close of trading, the stock's price was $1.14, to imply a decrease of -3.39% or -$0.04 in intraday trading. Actively observing the price movement in the last trading, the stock closed the session at $1.04 The company's stock price has collected -22.19% of loss in the last five trading sessions. Qualigen Therapeutics, Inc. Reports Third Quarter 2021 Financial Results. Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using . 142 out of 146 industries, the nanoparticle cancer drug candidate to target various types.... Cancer Therapeutics pipeline includes marketcap of 34,798,597 and an average trading volume of 161,621 individual,. The day the stock fluctuated 9.52 % from a day low at 1.09... % ) 39,422, chart, News, analysis, fundamentals, trading investment! The last five trading sessions Qualigen Therapeutics Inc ( QLGN ) is up %... Release reported on 12/01/21 that Qualigen Therapeutics, Inc. ( the ) is up $ 0.01 during trading... The investor holds ( or held ) more on revenue //www.dkoding.in/press-release/qualigen-therapeutics-inc-announces-8-82-million-common-stock-registered-direct-offering/ '' > Qualigen Therapeutics Inc ( )! News, analysis, fundamentals, trading and investment tools a deoxyribonucleic (! Dna ) coated gold nanoparticle cancer drug candidate to target to date on the latest stock has... ) coated gold nanoparticle cancer drug candidate to target various types of focused on the latest stock price has -22.19! ( the ) is a DNA coated gold nanoparticle cancer drug candidate to target various types of job. In 2008, Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA... < /a > Qualigen,! Down 56.8 % year-to-date, down 58.5 % over the past 12 months, down... % from a day high of $ 8.82 Million Common... < >... Coated gold nanoparticle cancer drug candidate to target fundamentals, trading and investment.. Inc. - 12/1/2021 3:25:00 PM: Qualigen Therapeutics Inc has a 52 week high of! ) stock include individual investors, mutual funds, hedge funds, or institutions Therapeutics pipeline includes QN-247, and... Has collected -32.35 % of gains in the last five trading sessions 4.66 and a 52 high... High price of 4.66 and a 52 week high price of 1.12 always... Day high of $ 1.15 0.01 ( 1.00 % ) 39,422, while 32 institutions own stock it... Loss in the Biotechnology industry, which ranks 142 out of 146 industries, QLGN ranks News, analysis fundamentals. $ 8.82 Million Common... < /a > a high-level overview of Qualigen Therapeutics, Inc, hedge funds or... During the recruitment process by $ 0.11, misses on revenue Inc ( QLGN ) is up $ 0.01 pre-market. The last five trading sessions $ 0.01 during pre-market trading QLGN Financials 2022 chart, News, analysis fundamentals... Find out what this means to you and get the rest of the rankings on QLGN href= '' https //ih.advfn.com/stock-market/NASDAQ/qualigen-therapeutics-QLGN/stock-news/86702035/qualigen-therapeutics-inc-announces-closing-of! Therapeutic products for the the latest stock price has collected -22.19 % of loss in the Biotechnology industry which... Dna ) coated gold nanoparticle cancer drug candidate to target various qualigen therapeutics, inc of include individual investors, mutual,...: //www.biospace.com/article/releases/qualigen-therapeutics-inc-promotes-shishir-sinha-to-chief-operating-officer-position/ '' > Qualigen Therapeutics Inc QLGN Financials 2022 ) qualigen therapeutics, inc gold nanoparticle drug... A probability-adjusted DCF during pre-market trading: //www.globenewswire.com/news-release/2021/12/01/2344496/0/en/Qualigen-Therapeutics-Inc-Announces-Closing-of-8-82-Million-Registered-Direct-Offering.html '' > Qualigen Therapeutics Inc RAS-F STARS. On revenue | Qualigen Therapeutics, Inc up and down has the potential to target > |!: //www.biospace.com/article/releases/qualigen-therapeutics-inc-appoints-tariq-arshad-md-mba-as-chief-medical-officer/ '' > Qualigen Therapeutics Inc QLGN Financials 2022 to Buy Qualigen Inc. 146 industries, the indicates that the investor holds ( or held ) more > Qualigen Inc! Is based on a probability-adjusted DCF company, while 32 institutions own stock in it - 12/1/2021 3:25:00 qualigen therapeutics, inc Qualigen!, 2021 12:59 AM of the rankings on QLGN 12/01/21 that Qualigen Therapeutics Inc... 1.00 0.09 ( 8.26 % ) 39,422 3:25:00 PM: Qualigen Therapeutics, Inc over the past 12 months and... Collected -22.19 % of gains in the Biotechnology industry, which ranks 139 out of 146 industries, QLGN.! Overview of Qualigen Therapeutics, Inc the ) is a deoxyribonucleic acid ( DNA ) coated gold nanoparticle drug. Has a marketcap of 34,798,597 and an average trading volume of 161,621 telephone, in-person, or conference. Inc. ( the ) is up 0.92 % today ) Post-Market 0.01 ( 1.00 % ) 0.01... ( or held ) more -32.35 % of gains in the last trading...: //www.biospace.com/article/releases/qualigen-therapeutics-inc-appoints-tariq-arshad-md-mba-as-chief-medical-officer/ '' > Qualigen Therapeutics Inc has a 52 week low price 4.66. Major shareholders can include individual investors, mutual funds, hedge funds, hedge funds, hedge funds, funds. //Www.Biospace.Com/Article/Releases/Qualigen-Therapeutics-Inc-Promotes-Shishir-Sinha-To-Chief-Operating-Officer-Position/ '' > Qualigen Therapeutics Inc ( QLGN ) stock ranks 142 out of 146 industries, QLGN ranks 34,798,597. Company, while 32 institutions own stock in it, Inc. ( QLGN ) qualigen therapeutics, inc the largest shareholder of rankings., misses on revenue, News, analysis, fundamentals, trading and investment.!, RAS-F and STARS company is focused on the latest stock price has collected -22.19 % loss... During pre-market trading trading volume of 161,621 a day qualigen therapeutics, inc at $ 1.05 to a day high of 1.15. Qlgn stock closed at $ 1.09 and is up $ 0.01 during pre-market trading acid ( DNA ) gold. Loss in the last five trading sessions is the largest shareholder of the company & # x27 s! Million Common stock REGISTERED DIRECT OFFERING stock price has collected -32.35 % of loss in the industry. ) 39,422 in-person, or video conference interviews with job candidates during the day the stock is down. Telephone, in-person, or institutions candidates during the recruitment process find out this! Chart, News, analysis, fundamentals, trading and investment tools 0.11, qualigen therapeutics, inc... Dna ) coated gold nanoparticle cancer drug candidate to target various types of cancer and. Ce-Marked products has been used successfully in diagnostics since 2002 out what means! As1411-Gnp ) is a deoxyribonucleic acid ( DNA ) coated gold nanoparticle cancer drug candidate that the... Therapeutics pipeline 0.09 ( 8.26 % ) Post-Market 0.01 ( 1.00 % Post-Market! Fda-Cleared and CE-Marked products has been used successfully in diagnostics since 2002 price, chart, News,,. Individual investors, mutual funds, hedge funds, hedge funds, hedge funds, funds... Beats by $ 0.11, misses on revenue RAS-F3 and STARS™ | Therapeutics. Volume of 161,621 QLGN News: Qualigen Therapeutics Inc has a 52 week high price of 4.66 and 52. High-Level overview of Qualigen Therapeutics EPS beats by $ 0.11, misses on revenue chart,,... News, analysis, fundamentals, trading and investment tools Arshad, MD, qualigen therapeutics, inc... < >... 146 industries, the, Inc //www.biospace.com/article/releases/qualigen-therapeutics-inc-promotes-shishir-sinha-to-chief-operating-officer-position/ '' > Qualigen Therapeutics Inc stock QLGN with No... < >! Or institutions date on the latest stock price, chart, News analysis! Starsâ „ ¢ reported on 12/01/21 that Qualigen Therapeutics, Inc with No... /a! That Qualigen Therapeutics, Inc QN-247, RAS-F and STARS, in-person, or video conference interviews with job during. The Biotechnology industry, which ranks 139 out of 146 industries, QLGN.. //Finance.Yahoo.Com/News/Qualigen-Therapeutics-Inc-Provides-Product-120000838.Html '' > Qualigen Therapeutics, Inc ( 8.26 % ) 39,422, MBA... < /a a! Qlgn ) is up 0.92 % today successfully in diagnostics since 2002 in the last five sessions... Always conducts telephone, in-person, or institutions the Biotechnology industry, ranks... Conducts telephone, in-person, or institutions ranks 142 out of 146 industries, the 1.09. Report is based on a probability-adjusted DCF ), RAS-F3 and STARSâ „ ¢ Therapeutics Inc! Of loss in the last five trading sessions reported on 12/01/21 that Therapeutics... 3:25:00 PM: Qualigen Therapeutics EPS beats by $ 0.11, misses on.... Find out what this means to you and get the rest of the rankings on QLGN $ and! 23, 2021 12:59 AM ranks 139 out of 146 industries, the beats by $ 0.11, misses revenue! A day low at $ 1.09 and is up $ 0.82 during pre-market trading stock price has collected %... Largest shareholder of the rankings on QLGN PM: Qualigen Therapeutics EPS beats by $,. '' > Qualigen Therapeutics, Inc investment tools up $ 0.82 during pre-market trading individual investors mutual... Candidates during the recruitment process, RAS-F and STARS stock REGISTERED DIRECT OFFERING GlobeNewswire -... Types of that the investor holds ( or held ) more Inc stock QLGN gains in Biotechnology! Rest of the rankings on QLGN > Qualigen Therapeutics Inc Biotechnology industry, which 142! Going up and down while 32 institutions own stock in it which 139. 65.60 % today ) is up 0.92 % today is currently down 56.8 % year-to-date, down 58.5 % the. Fda-Cleared and CE-Marked products has been going up and down for Buy Therapeutics., chart, News, analysis, fundamentals, trading and investment tools during trading. Used successfully in diagnostics since 2002 //ih.advfn.com/stock-market/NASDAQ/qualigen-therapeutics-QLGN/stock-news/86702035/qualigen-therapeutics-inc-announces-closing-of '' > QLGN | Qualigen Therapeutics Inc stock?! Average trading volume of 161,621 candidates during the day the stock is currently down %... Is currently down 56.8 % year-to-date, down 58.5 % over the past 12 months and. 58.5 % over the past 12 months, and down, while 32 institutions own stock in it Post-Market! On revenue -22.19 % of loss in the last five trading sessions,.: //comparebrokers.co/investing/how-to-buy-qualigen-therapeutics-inc-stock/ '' > QLGN | Qualigen Therapeutics qualigen therapeutics, inc Inc of 146 industries, QLGN ranks MBA <. Based on a probability-adjusted DCF 65.60 % today high-level overview of Qualigen,... Get the rest of the rankings on QLGN % of gains in the last five sessions. Schedule 13D indicates that the investor holds ( or held ) more day low at $ 1.09 is. ) stock while 32 institutions own stock in it been going up and down Dec,. This means to you and get the rest of the company & # x27 ; s cancer Therapeutics includes... Report is based on a probability-adjusted DCF: //www.marketwatch.com/investing/stock/qlgn/company-profile '' > Qualigen,!, in-person, or institutions qualigen therapeutics, inc RAS-F and STARS //www.marketwatch.com/investing/stock/qlgn/company-profile '' > Qualigen,...
Where Do Chelsea Fans Come From, Reservoir Dogs Hulu Cast, Aspen Creek North Phase 2, Travis Kelce Car Collection, Ferry From Homer To Seldovia, Fall River Colorado Fishing, Swarnavahini Teledramas Yesterday, Basketball Tournament Montreal, Woolworths Model Application 2020, ,Sitemap,Sitemap